Is NCT06846463 recruiting in Richmond, VA?

Yes, NCT06846463 is currently recruiting participants at its Richmond, VA location. This diffuse large b-cell lymphoma clinical trial is actively enrolling qualified participants.

How do I join the diffuse large b-cell lymphoma clinical trial in Richmond?

To join this clinical trial in Richmond, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Richmond clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Diffuse Large B-cell Lymphoma Clinical Trial in Richmond, VA

About This Diffuse Large B-cell Lymphoma Study in Richmond

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

Sponsor: Virginia Commonwealth University

Who Can Participate

Inclusion Criteria

Patients must have a documented pathologic diagnosis of DLBCL at any stage.

Must have documented MYD88 L265P, CD79B, or NOTCH1 truncation mutation or be CD5+ by IHC.

Age ≥18 years on the day of signing the informed consent form.

Patients must have measurable disease on Positron Emission Tomography-Computed Tomography scan (CT/PET) imaging.

Patient must have received no more than one cycle of R-CHOP prior to enrollment. Length of time between first R-CHOP treatment and planned 2nd R-CHOP treatment should vary by no more than 21 days ± 3 days.

Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

Adequate bone marrow function as defined by:

Absolute neutrophil count (ANC) ≥1000/mm3, except for patients with bone marrow involvement in which ANC must be ≥500/mm3.

Platelet ≥75,000/mm3, except for patients with bone marrow involvement in which the platelet count must be ≥30,000/mm3.

Hemoglobin ≥7 g/dL, after transfusion if necessary

Adequate organ function defined as:

Creatinine clearance ≥30 mL/min as estimated by the Cockcroft-Gault equation.

Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase, and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase ≤2.5 × upper limit of normal (ULN).

Serum total bilirubin ≤3 x ULN (except patients with Gilberts syndrome 3g/dl).

Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.

Women of childbearing potential and men must agree to use one of the following highly effective forms of birth control during the treatment and for 1 month following completion of study treatment for women and for 1 week following completion of study treatment for men.

combined (estrogen and progestogen containing) hormonal contraception:

intravaginal

transdermal

progestogen-only hormonal contraception associated with inhibition of ovulation

implantable

intrauterine device (IUD)

intrauterine hormone-releasing system (IUS)

bilateral tubal occlusion

vasectomized partner

heterosexual abstinence

Patients must not have any known allergies, hypersensitivity or intolerance to corticosteroids or monoclonal antibodies.

Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.

Exclusion Criteria

Patients with high grade B-cell lymphoma with myelocytomatosis oncogene /immunoglobulin heavy-chain (MYC)/IGH and BCL-2 rearrangements.

Patients with brain metastasis.

Patients with peripheral neuropathy CTCAE grade ≥2.

Any uncontrolled or clinically significant cardiovascular disease including the following:

Myocardial infarction within 6 months before screening.

Unstable angina within 3 months before screening.

New York Heart Association class III or IV congestive heart failure.

History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes).

Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer.

History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.

History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.

Severe or debilitating pulmonary disease in the opinion of the treating investigator.

Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

Active fungal, bacterial and/or viral infection requiring systemic therapy.

Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs.

Active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:

Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (\< 20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation.

Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable.

Major surgery within 4 weeks of the first dose of study drug.

Pregnant or lactating women.

Left ventricular ejection fraction (LVEF) \<55% on screening echocardiogram.

Vaccination or requirement for vaccination with a live vaccine within 28 days prior to the first dose of study drug or at any time during planned study treatment.

Hypersensitivity to zanubrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, or prednisone.

Requires ongoing treatment with a strong CYP3A inducer (Table 3).

Concurrent participation in another therapeutic clinical trial.

Active and/or ongoing autoimmune anemia and/or autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura).

Requires ongoing treatment with warfarin or warfarin derivatives.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT06846463) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diffuse Large B-cell Lymphoma Treatment Options in Richmond, VA

If you're searching for diffuse large b-cell lymphoma treatment options in Richmond, VA, this clinical trial (NCT06846463) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diffuse large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diffuse large b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

Diffuse Large B-cell Lymphoma Clinical Trial in Richmond, VA

Expert Care in Richmond

IRB Approved

No-Cost Care

Apply for This Richmond Location

Why Participate?

Simple Process